News | Antiplatelet and Anticoagulation Therapies | March 21, 2016

Novel Oral Anticoagulants Predicted to Challenge Warfarin in VTE Treatment

GlobalData analyst says NOACs will recover from slow initial uptake due to fast action, elimination of regular coagulation monitoring

NOACs, novel oral anticoagulants, VTE treatment, venous thromboembolism, GlobalData

March 21, 2016 — The use of novel oral anticoagulants (NOACs) will see a substantial rise after an initially sluggish uptake and will start to be elected over warfarin, according to an analyst with research and consulting firm GlobalData. Warfarin is the current standard-of-care product in certain indications. 

Lakshmi Dharmarajan, Ph.D., GlobalData's senior analyst covering cardiovascular and metabolic disorders, stated that: “NOACs are increasingly being used in patients with venous thromboembolism (VTE) due to the drugs’ rapid onset of action and the ability to be administered in fixed doses without the need for regular coagulation monitoring.

“Among the VTE population, the fastest to adopt NOACs have been the orthopedic patient segments, for the prevention of deep vein thrombosis (DVT).”

For those with DVT, Xarelto has been demonstrated by real-world studies to have economic advantages over standard-of-care treatments.

As Dharmarajan explained: “Positive evidence such as shorter hospital stays, in addition to the obvious clinical benefits of these drugs, will encourage payers and healthcare systems to recognize their financial advantages over existing treatments.

“For the anticoagulation market in general, a concerted effort by NOAC manufacturers to provide clinical practice evidence is absolutely essential for these drugs to challenge the 65-year legacy built by warfarin.”

Fortunately for such manufacturers, the launch of reversal agents will help boost NOAC usage in the near future. Even in cost-conscious markets such as the United Kingdom, physicians envision a dramatic shift towards NOACs, at least for the majority of the VTE population.

“For NOAC developers, the next step should be to evaluate the efficacy and safety of the drugs for patients with VTE and cancer, and also for the prophylaxis of VTE. This would enable the treatment to achieve universal acceptance in the VTE population as the standard-of-care therapy,” the analyst concluded.

For more information: www.globaldata.com

Related Content

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to p
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S.
aspirin bottle
News | Antiplatelet and Anticoagulation Therapies | December 12, 2019
December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African Ame
Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., explains the reasons for shorter duration dual-...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not...
Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019
New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC...
Overlay Init